Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Adma Biologics (ADMA)

Adma Biologics (ADMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,591,170
  • Shares Outstanding, K 238,159
  • Annual Sales, $ 510,170 K
  • Annual Income, $ 146,930 K
  • EBIT $ 192 M
  • EBITDA $ 200 M
  • 60-Month Beta 0.82
  • Price/Sales 5.14
  • Price/Cash Flow 16.83
  • Price/Book 5.49

Options Overview Details

View History
  • Implied Volatility 96.54% (+0.58%)
  • Historical Volatility 98.71%
  • IV Percentile 92%
  • IV Rank 52.78%
  • IV High 147.60% on 03/27/26
  • IV Low 39.48% on 01/22/26
  • Expected Move (DTE 24) 1.93 (17.90%)
  • Put/Call Vol Ratio 0.16
  • Today's Volume 2,998
  • Volume Avg (30-Day) 9,125
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 127,802
  • Open Int (30-Day) 133,741
  • Expected Range 8.85 to 12.71

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $0.14
  • Growth Rate Est. (year over year) +713,471.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.21 +49.51%
on 03/26/26
14.84 -27.36%
on 03/23/26
-3.54 (-24.72%)
since 03/20/26
3-Month
7.21 +49.51%
on 03/26/26
18.00 -40.11%
on 02/03/26
-6.58 (-37.90%)
since 01/21/26
52-Week
7.21 +49.51%
on 03/26/26
25.67 -58.01%
on 04/28/25
-8.86 (-45.11%)
since 04/21/25

Most Recent Stories

More News
ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating

ADMA Investors with Losses Encouraged to Contact the Firm

ADMA : 10.78 (-0.92%)
Securities Fraud Investigation Into ADMA Biologics, Inc. (ADMA) Continues – Shareholders Who Lost Money Urged to Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Glancy Prongay Wolke & Rotter LLP , a leading national shareholder rights law firm, continues its investigation on behalf of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:  ...

ADMA : 10.78 (-0.92%)
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA

NEW YORK , April 20, 2026 /PRNewswire/ --

ADMA : 10.78 (-0.92%)
ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Law Offices of Howard G. Smith continues its investigation on behalf of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:  ADMA ) investors concerning the Company’s possible...

ADMA : 10.78 (-0.92%)
Securities Fraud Investigation Into ADMA Biologics, Inc. (ADMA) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz continues its investigation of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:  ADMA ) on behalf of investors concerning the Company’s...

ADMA : 10.78 (-0.92%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA

NEW YORK , April 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised...

ADMA : 10.78 (-0.92%)
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA

NEW YORK , April 15, 2026 /PRNewswire/ --

ADMA : 10.78 (-0.92%)
ADMA Investor Alert: ADMA Biologics Securities Fraud Investigation - Investors With Losses May Seek to Lead the Potential Class Action After Company Allegedly Concealed Revenue Headwinds: Levi & Korsinsky

ADMA Biologics guided 2026 revenue to at least $635 million -- built on a 2025 revenue base a short-seller report alleges was inflated by as much as 23 percentage points.

ADMA : 10.78 (-0.92%)
ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating

SAN FRANCISCO , April 14, 2026 /PRNewswire/ -- Investors in ADMA Biologics, Inc. (NASDAQ: ADMA) saw the price of their shares slide over 16% on March 24, 2026 on short seller Culper Research's...

ADMA : 10.78 (-0.92%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA

NEW YORK , April 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised...

ADMA : 10.78 (-0.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying...

See More

Key Turning Points

3rd Resistance Point 11.89
2nd Resistance Point 11.61
1st Resistance Point 11.19
Last Price 10.78
1st Support Level 10.50
2nd Support Level 10.22
3rd Support Level 9.81

See More

52-Week High 25.67
Fibonacci 61.8% 18.62
Fibonacci 50% 16.44
Fibonacci 38.2% 14.26
Last Price 10.78
52-Week Low 7.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.